Echocardiographic Predictors of Atrial Fibrillation

  • STATUS
    Recruiting
  • participants needed
    200
  • sponsor
    Karl Landsteiner University of Health Sciences
Send
Updated on 19 September 2021
See if I qualify
stroke
stenosis
MRI
mitral stenosis
ejection fraction
angiography
ischemia
myocardial infarction
atherosclerosis
electrocardiogram
infarct
transient ischemic attack
fibrillation
holter monitor
embolism
hypercoagulability
ambulatory ecg

Summary

This prospective study aims to identify the diagnostic accuracy of echocardiographic predictors of atrial fibrillation in patients with ESUS (embolic stroke of undetermined source) or TIA (transient ischemic attack).

Description

Cardiac thromboembolism attributed to atrial fibrillation (AF), the most frequent cardiac arrhythmia, is responsible for up to one-third of ischemic strokes.
Several factors have been proposed to predict AF, as findings in 12-lead ECG (electrocardiogram) or Holter ECG, epidemiological or echocardiographic parameters.
The main purpose of this research project is to test the diagnostic accuracy of the atrial electromechanical conduction time, measured as septal total atrial conduction time "sPA-TDI", an echocardiographic parameter, and the LaHAsPa-Score, which is based on patient characteristics and echocardiographic measurements for the detection of AF in patients diagnosed with ESUS or TIA, utilizing a 7-day ambulatory ECG monitor and incidental detection of AF during a two-year follow-up period, including detection via implantable cardiac monitor or pacemaker, if applicable.
Other echocardiographic measurements including left atrial volume index (area-length method), atrial electromechanical delay, left atrial myocardial strain together with laboratory, 12-channel ECG, Holter ECG findings, and established risk scores will be compared to the main parameters of interest.
The investigators expect that the results will help with better risk stratification and targeted monitoring periods for atrial fibrillation in patients with ESUS or TIA.

Details
Condition stroke, Transient Ischemic Attack, Ischemic, Embolic Stroke of Undetermined Source, Atrial Fibrillation (Pediatric), Atrial Fibrillation, Dysrhythmia, Arrhythmia
Age 18years - 100years
Treatment ECG monitoring
Clinical Study IdentifierNCT05044208
SponsorKarl Landsteiner University of Health Sciences
Last Modified on19 September 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age 18 years, written informed consent to participate in the study Clinical
diagnosis of ischemic stroke or transient ischemic attack + brain imaging to
rule out hemorrhagic stroke
Stroke: ESUS, defined as all of the following
Stroke detected by CT (computertomography) or MRI (magnetic resonance imaging) that is not lacunar. (Lacunar is defined as a subcortical (this includes pons and midbrain) infarct in the distribution of the small, penetrating cerebral arteries whose largest dimension is 1.5 cm on CT or 2.0 cm on MRI diffusion images/<1.5 cm on T2 weighted MR images. The following are not considered lacunes: multiple simultaneous small deep infarcts, lateral medullary infarcts, and cerebellar infarcts.)
Absence of extracranial or intracranial atherosclerosis causing 50 percent luminal stenosis of the artery supplying the area of ischemia. Patients must undergo vascular imaging of the extracranial and intracranial vessels using either catheter angiography, CT angiogram (CTA), MR angiogram (MRA), or ultrasound, as considered appropriate by the treating physician and local principal investigator
No major-risk cardioembolic source of embolism, including intracardiac thrombus, mechanical prosthetic cardiac valve, atrial myxoma or other cardiac tumors, mitral stenosis, myocardial infarction within the last 4 weeks, left ventricular ejection fraction <30 percent, valvular vegetations, or infective endocarditis)
No other specific cause of stroke identified, such as arteritis, dissection, migraine, vasospasm, drug abuse, or hypercoagulability. Special testing, such as toxicological screens, serological testing for syphilis, and tests for hypercoagulability, will be performed at the discretion of the treating physician and local principal investigator, if needed
TIA: Patients fulfilling all above criteria and diagnostic work-up, except the detection of ischemic lesions by CT or MRI is optional and clinical symptoms last < 1 hours
All patients must undergo electrocardiogram, transthoracic or transesophageal
echocardiography (TTE or TEE) and at least 24 hours of cardiac rhythm
monitoring (Holter monitor or telemetry or equivalent)
Patent foramen ovale is not an exclusion criterion. Planned or existing
implantation of an implantable cardiac monitor or cardiac pacemaker is not an
exclusion criterion

Exclusion Criteria

History of AF, AF on 12-lead ECG, or any AF of any duration during heart-rhythm monitoring prior to inclusion into the study
Technical problems or bad quality of the echocardiogram making it impossible to measure the main parameters for calculating the LaHAsPa-Score (sPA-TDI, LAVI)
Wearing time < 1 week (combined recording time < 168 hours) due to patient withdrawing from study, patch dissolving or technical defects
Life expectancy < 1 month
Patients under custody or mentally not being able to give written informed consent
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

stroke
stenosis
MRI
mitral stenosis
ejection fraction
angiography
ischemia
myocardial infarction
atherosclerosis
electrocardiogram
infarct
transient ischemic attack
fibrillation
holter monitor
embolism
hypercoagulability
ambulatory ecg

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.